COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Protocol No
MIRATI-849-002
Principal Investigator
Ben George
Phase
I/II
Summary
This study will evaluate if patients with cancer with a KRAS G12C mutation will benefit from treatment with MRTX849 and TNO155. It will also look at what side effects occur and how often, they occur. Other objectives of the study include assessing how quickly MRTX849 and TNO155 are absorbed into the blood stream and how fast it is removed by the body. Several laboratory tests will be performed using samples of tumor tissue or blood to understand how and why the drug may work.
Description
MRTX849 is an investigational drug that is designed to target proteins produced by a specific
gene mutation (KRAS G12C mutation) that is thought to cause cancer cells to grow. MRTX849
is designed to block this mutant protein and thereby prevent the growth and spread of the cancer.

Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL